Pharmaron Beijing Co Ltd (300759) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Pharmaron Beijing Co Ltd stock ¥24.78, price ¥42.43, that is 41.6% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.
How to read this chart
60‑month range ¥17.72 – ¥99.56 · fair‑value band ¥13.54 – ¥30.97 · the ¥42.43 price screens above the ¥24.78 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 11, 2026.
Follow Pharmaron Beijing Co in your weekly email
Every Wednesday you see whether Pharmaron Beijing Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Pharmaron Beijing Co., Ltd., together with its subsidiaries, operates as a pharmaceutical research and development service platform in North America, Europe, the Mainland China, Asia, and internationally.
Show moreShow less
It operates through five segments: Laboratory Services; Chemical and Formulation Process Development and Manufacturing Services; Clinical Research Services; Macromolecule and Cell and Gene Therapy Services; and Others.
The company offers laboratory chemistry and biological science services, including small molecule chemical drugs, oligonucleotides, peptides, antibodies, antimicrobial agents, antibody-drug conjugates (ADCs), and cell and gene therapy products; small molecule CDMO services, such as API process development and production, material science and preformulation, formulation development, and analytical development.
It also provides clinical research services; macromolecular and cell and gene therapy services comprising drug discovery, development and production services, cell and gene therapy laboratory services, and gene therapy drug development and production services.
In addition, the company is involved in the provision of technology development, technology transfer, technical consultation, technical services, and technical training; import and export of goods and technologies.
Pharmaron Beijing Co., Ltd. was incorporated in 2004 and is headquartered in Beijing, the People's Republic of China.
Stock analysis
Pharmaron Beijing Co Ltd (300759) currently trades at ¥42.43, while our model-based Fair Value estimate is ¥24.78, 42% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ¥37.54 per share, and 2 of the 26 models we run sit above the ¥42.43 price.
Bear case: the Asset-Based group reads lowest at ¥4.66, and 24 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ¥13.54 (bear) to ¥30.97 (bull), the price of ¥42.43 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Pharmaron Beijing Co Ltd reported revenue of 14.1B CNY in FY2025 versus 7.4B CNY in FY2021, a compound +17.3%/yr. Reported net income was 1.7B CNY in FY2025, compounding +0.0%/yr from FY2021.
Key figures
Market cap 76.3B CNY (≈ $11.4B) Large · P/E ratio 46.4 · P/S ratio 4.77 · EPS (TTM) ¥0.9800 · Dividend yield 0.5% · Net margin 11.1% · Return on equity 10.4% · Return on assets (EBIT) 8.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 97% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −42%, 300759 screens richer than that median.
Fair Value models
Bear¥13.54Fair Value ¥24.78Bull¥30.97
Price ¥42.43 · Downside -41.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (¥0.6796 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.4%
Start year 2020 (pandemic). Over 10 years: +28.7% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−8.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.8%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−8.8% vs 20.4%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.26% → 16%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+45.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+17.4%
Yearly sales growth analysts expect, extended to five years.
Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain.
After inflation (China: IMF forecast 1.7% a year to 2030, 1.4% from 2016 to 2025) that is about +43.2% a year for the price and +15.5% for the forecasts.
Compare Pharmaron Beijing Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Top 25%
Fair Value upside−41.6% · Bottom 25%
Profitability
Return on equity (12 months)10.4% · Top 25%
Return on assets6.1% · Top 25%
Net margin (12 months)11.1% · Above median
Operating margin (12 months)15.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)20.9% · Above median
Dividend yield (12 months)0.5% · Below median
Balance sheet
Debt / equity0.12× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Pharmaron Beijing Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300759
Frequently asked questions
Is Pharmaron Beijing Co Ltd (300759) overvalued or undervalued?
As of Nov 11, 2026, our model estimates a fair value of ¥24.78 versus a price of ¥42.43, about 42% lower (overvalued).
What is the fair value of 300759?
Our model-based fair value for Pharmaron Beijing Co Ltd is ¥24.78 (as of Nov 11, 2026), built from audited fundamentals. The current price: ¥42.43.
What is the quality score of 300759?
Pharmaron Beijing Co Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pharmaron Beijing Co Ltd (300759)?
Our model-based price target is the fair value of ¥24.78 (as of Nov 11, 2026) from 26 valuation models. Cautious scenario ¥13.54, optimistic scenario ¥30.97. It is a calculation from audited fundamentals, not an analyst target.
What is the Pharmaron Beijing Co Ltd stock forecast for 2026?
Our models put fair value at ¥24.78, about 42% lower versus a price of ¥42.43 (overvalued). Cautious scenario ¥13.54, optimistic scenario ¥30.97. The calculation is refreshed regularly with new filings.
What is the revenue of Pharmaron Beijing Co Ltd (300759)?
Pharmaron Beijing Co Ltd reported trailing-twelve-month revenue of about 16.0B CNY (latest available figure, as of Nov 11, 2026).
Does Pharmaron Beijing Co Ltd pay a dividend?
Pharmaron Beijing Co Ltd currently shows a dividend yield of 0.47% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Pharmaron Beijing Co Ltd (300759) and when is the ex-dividend date?
Pharmaron Beijing Co Ltd pays a dividend of ¥0.2 per share a year, a dividend yield of 0.5%. The last ex-dividend date was Jul 7, 2026. A dividend has been paid every year since at least 2019. The payout ratio is 20.4% of earnings. Free cash flow covers the dividend 1.87 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Pharmaron Beijing Co Ltd (300759)?
For today's price to be fair in a discounted-cash-flow model, Pharmaron Beijing Co Ltd would have to grow free cash flow by +45.6 % per year for five years (discount rate 9.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +22.4 % per year. Calculated on free cash flow for fiscal year 2025. Over the last twelve months it was negative, so the figure above is uncertain. As of Nov 11, 2026.
What discount rate (WACC) does the fair value of 300759 use?
Our models discount Pharmaron Beijing Co Ltd at 9.1 %: a base by market capitalisation (large), damped by beta 0.69, country premium for China. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pharmaron Beijing Co Ltd that is +45.6 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.1 %) and the same formula as our fair value.
How much growth has Pharmaron Beijing Co Ltd (300759) delivered so far?
Over the past 5 years revenue at Pharmaron Beijing Co Ltd grew +22.4 % a year. The price currently implies free-cash-flow growth of +45.6 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pharmaron Beijing Co Ltd (300759) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Pharmaron Beijing Co Ltd (+45.6 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pharmaron Beijing Co Ltd (300759)?
The free-cash-flow yield on the price is 0.73 % in the last fiscal year (free cash flow was negative over the last twelve months): that much free cash flow Pharmaron Beijing Co Ltd produces per unit of market value. When it exceeds the discount rate of our models (9.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pharmaron Beijing Co Ltd (300759)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pharmaron Beijing Co Ltd it is ¥24.78 per share (as of Nov 11, 2026), against a price of ¥42.43. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Pharmaron Beijing Co Ltd stock overvalued or undervalued in 2026?
As of Nov 11, 2026, 300759 trades above its calculated fair value: price ¥42.43, fair value ¥24.78, a gap of about −42% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300759?
No. The price is what the market pays today (¥42.43); the fair value is what the company's own numbers justify (¥24.78). For Pharmaron Beijing Co Ltd the two are ¥17.65 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pharmaron Beijing Co Ltd worth?
The market values Pharmaron Beijing Co Ltd at about 76.3B CNY (market capitalisation, as of Nov 11, 2026). Per share that is ¥42.43; our models calculate a fair value of ¥24.78 per share.
What do the bullish and bearish scenarios say about 300759?
Our models span a range for Pharmaron Beijing Co Ltd: cautious scenario ¥13.54, base ¥24.78, optimistic ¥30.97 per share (as of Nov 11, 2026, price ¥42.43). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300759?
Pharmaron Beijing Co Ltd trades at a price-to-earnings ratio of 46.4 (as of Nov 11, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥24.78 is built from several models across several years. Other multiples: P/B 5.1, P/S 4.8, EV/EBITDA 23.0.
How solid is the balance sheet of Pharmaron Beijing Co Ltd (300759)?
Balance-sheet figures for Pharmaron Beijing Co Ltd (as of Nov 11, 2026): return on equity 10.4%, debt of 0.12 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 300759 from its 52-week high?
Pharmaron Beijing Co Ltd trades at ¥42.43, about 17% below its 52-week high of ¥51.15 and 97% above the low of ¥21.58 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥24.78 is for.
Which stocks are comparable to Pharmaron Beijing Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pharmaron Beijing Co Ltd stock attractive at the current price?
The data as of Nov 11, 2026: price ¥42.43, calculated fair value ¥24.78 (−42%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300759 calculated?
We run Pharmaron Beijing Co Ltd through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥24.78 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.9% above its aggregate fair value. Pharmaron Beijing Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pharmaron Beijing Co Ltd (300759)?
The closing price on Nov 13, 2026 was ¥42.43. Our model-based fair value is ¥24.78, about 42% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pharmaron Beijing Co Ltd right now?
The price sits above even our optimistic bull case (¥30.97). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (¥13.54 to ¥30.97) leaves room in how you read the outcome.
Where does the earnings growth of Pharmaron Beijing Co Ltd (300759) come from?
Earnings per share at Pharmaron Beijing Co Ltd grew +30.4 % a year from 2014 to 2024. Broken into its drivers: revenue per share +15.4 %, EBIT margin +14.9 %, tax rate +0.3 %, residual (interest, one-offs) −1.9 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Pharmaron Beijing Co Ltd
How large is the market capitalisation of Pharmaron Beijing Co Ltd (300759)?
The market capitalisation of Pharmaron Beijing Co Ltd is 76.3B CNY (≈ $11.4B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pharmaron Beijing Co Ltd (300759)?
The price-to-sales ratio of Pharmaron Beijing Co Ltd is 4.77 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pharmaron Beijing Co Ltd (300759)?
Earnings per share at Pharmaron Beijing Co Ltd are ¥0.9800 (price ÷ EPS = P/E 46.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pharmaron Beijing Co Ltd (300759)?
The dividend yield of Pharmaron Beijing Co Ltd is 0.5% (payout 20.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pharmaron Beijing Co Ltd (300759)?
The net margin of Pharmaron Beijing Co Ltd is 11.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pharmaron Beijing Co Ltd (300759)?
The return on equity (ROE) of Pharmaron Beijing Co Ltd is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pharmaron Beijing Co Ltd (300759)?
On an EBIT basis the return on assets of Pharmaron Beijing Co Ltd is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pharmaron Beijing Co Ltd (300759)?
The operating margin of Pharmaron Beijing Co Ltd is 15.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pharmaron Beijing Co Ltd (300759)?
Revenue at Pharmaron Beijing Co Ltd is growing +20.9% versus a year earlier (3y avg +11.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pharmaron Beijing Co Ltd (300759)?
Earnings per share at Pharmaron Beijing Co Ltd are growing +8.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pharmaron Beijing Co Ltd (300759) carry?
The net debt of Pharmaron Beijing Co Ltd is 2.0B CNY (fiscal year 2025, ≈ 3.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Pharmaron Beijing Co Ltd in the live analysis
One click puts Pharmaron Beijing Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 11, 2026